Sanofi ADS (SNY) Analyst Ratings & Price Targets

Sanofi ADS

SNY · Nasdaq

Analyst Consensus

Hold

13 analysts

$43

Current

—

Low

$55

Average

—

High

Average target implies +25.52% versus the current price.

Analyst Ratings Synthesis

The consensus rating is Hold, supported by 13 analysts. The target data provide only a mean of $54.5; the low and high targets are unavailable, so no target cluster or spread can be measured. The evidence does not identify which named analyst or firm is most bullish or least bullish. It also contains no attributable target revisions during the week, leaving the direction of estimate changes unestablished. The substantive tension visible in the supplied research is between Sanofi's strong commercial execution—particularly Dupixent, newer launches and the raised 2026 outlook—and investor concern over pipeline setbacks and sharply lower reported net profit. No analyst-specific explanation resolves that disagreement.

Rating Actions

No individual rating actions have been captured for SNYyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

BERENBERG BANK

DBS BANK

DEUTSCHE BK SEC

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

TD COWEN

UBS

ZACKS RESEARCH

Symbol: SNY
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Key Issues

Bullish view

Dupixent surpassed €5 billion in quarterly sales for the first time, while recently launched medicines, strong sales and cost discipline supported double-digit second-quarter growth. That momentum can lessen the near-term impact of pipeline disappointments.

Bearish view

The market still pushed the shares sharply lower after the earnings beat and raised outlook because pipeline setbacks remain a strategic concern. Strong current products may not resolve longer-term growth questions.

Analyst Consensus

See all

Hold

13 analysts

$43

Current

—

Low

$55

Average

—

High

Average target implies +25.52% versus the current price.

Earnings History

BeatMissNo estimate

Sanofi ADS

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers